Friday, 22 Jun 2018

You are here

Increased Risk of Depression and Anxiety in Rheumatoid Arthritis

Canadian researchers have analyzed population data and shown that the incidence and prevalence of depression, anxiety  and bipolar disorders are elevated in the rheumatoid arthritis (RA) patients compared to a matched population.

Estimates on the prevalence of depression and anxiety in RA patients vary widely in the literature. Thus, investigators analyzed population‐based administrative health data from Manitoba, Canada, to identify RA patients and a 5:1 matched control population to estimate the incidence and prevalence of depression, anxiety disorder, bipolar disorder, and schizophrenia. 

Among 10,206 incident cases of RA and 50,960 matched individuals, adjusted incidence rates were reported:

  • Depression: was higher in the RA patients (incidence rate ratio [IRR] 1.46 [95% confidence interval (95% CI) 1.35–1.58]). The lifetime and annual period prevalence of depression was also higher in RA.
  • Anxiety: was higher in RA patients (IRR 1.24 [95% CI 1.15–1.34]). The lifetime and annual period prevalence of anxiety was also higher in RA 
  • Bipolar disorder was also higher (IRR 1.21 [95% CI 1.00–1.47]).
  • Not significant: the frequency of schizophrenia did not differ between groups (IRR 0.96 [95% CI 0.61–1.50]).

The risks of depression, anxiety disorder, and bipolar disorder have not changed over time, despite substantial changes in the clinical management of RA over the 20‐year study period.

Clinicians should be aware that women and those of lower socioeconomic status are at particularly increased risk of these disorders.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Seronegative and Seropositive Rheumatoids Respond Equally Well

A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR  classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.

Does RA kill you? Let me count the ways….and what you can do about it

There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.

FDA Approves Low Dose Baricitinib for Rheumatoid Arthritis

The US Food and Drug Administration has approved baricitinib (Olumiant) for use in adults in moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to TNF inhibitors (TNFi). It is not approved for use, nor has it been studied, in children.

FDA Approves Baricitinib 2 mg for Rheumatoid Arthritis

Today the U.S. Food and Drug Administration approved baricitinib (Oluminant) at the lower dose of 2 mg per day for use in adults with with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to commonly-used treatments known as TNF inhibitors.